Real-world efficacy of tirzepatide in patients with heart failure without diabetes

Jan 31, 2025Current problems in cardiology

How tirzepatide works in heart failure patients who don’t have diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

In a cohort of 897 patients, untreated individuals had a 3.12-fold higher risk of acute heart failure compared to those treated with tirzepatide.

Tirzepatide is associated with a significantly reduced risk of incident acute heart failure.
Patients not treated with tirzepatide showed a 3.57-fold higher risk of major adverse cardiovascular events.
The risk of stroke was 2.796 times greater in untreated patients compared to those receiving tirzepatide.
Chronic kidney disease and coronary arterial disease risks were also higher in the untreated group, with hazard ratios of 1.48 and 1.474, respectively.

AI simplified

BACKGROUND: Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown significant cardiovascular benefits in clinical trials. This study investigates the real-world impact of tirzepatide on heart failure (HF) outcomes, leveraging data from the TriNetX platform.

METHODS: Using data from January 1, 2013, to December 01, 2024, we conducted a propensity-matched analysis of two cohorts of patients with HF without diabetes, where the only difference was the use of tirzepatide. The primary outcome was the incidence of acute heart failure (acute HF), with secondary outcomes including major adverse cardiovascular events (MACE), chronic kidney disease (CKD), stroke, and coronary arterial disease (CAD).

RESULTS: After propensity-matching, 897 patients were compared between the two cohorts in a 4-year follow-up, showing that untreated patients were at higher risk of incident acute HF (HR: 3.12, 95 %CI = 2.240-4.349, log-rank p < 0.001) and MACE (HR: 3.57, 95 %CI = 2.32-5.48, log-rank p < 0.001). Stroke (HR: 2.796, 95 %CI = 1.353-5.776, log-rank p < 0.01), CKD (HR: 1.48, 95 %CI: 1.08-2.03, log-rank p = 0.015), and CAD (HR: 1.474, 95 %CI,1.169-1.859, log-rank p = 0.001) outcomes also favored the treatment cohort.

CONCLUSION: Tirzepatide presents a promising therapeutic option for managing heart failure, with significant metabolic and cardiovascular benefits. These real-world findings reinforce its potential role as a transformative treatment in improving clinical outcomes and quality of life for patients with HF without diabetes.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (XML) ↗View full text ↗

Real-world efficacy of tirzepatide in patients with heart failure without diabetes

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief